Introduction
Hypertension is a complex condition and the most common cause for cardiovascular disease worldwide. The microcirculation plays an important role in its pathophysiology since primarily small arteries and arterioles determine peripheral resistance. Their function, and particularly that of the vascular endothelium, is compromised in patients with hypertension resulting in reduced vasodilation and enhanced vascular tone associated with a pro-inflammatory and pro-thrombotic state. 1, 2 Inflammation localized in vascular tissue is an important contributor to endothelial dysfunction and hence, the pathophysiology of hypertension. [3] [4] [5] However, it remains elusive whether inflammation is primarily cause or consequence of hypertension, though there is evidence that supports either scenario in a likely vicious way. 4, 6 Experimental studies have strengthened the concept of an immunologic basis for hypertension as the absence of T-cells markedly blunted the elevation of blood pressure (BP) in several forms of hypertension. [7] [8] [9] Although the mechanisms underlying the mediator effect of T-cells on hypertension remain poorly understood, several consequences of T-cell activation evolve as key players in the development of hypertension. 10 Growing evidence supports an essential role for sphingosine-1-phosphate (S1P) and its signalling axis in the regulation of the vascular system and a number of immune cell functions. 11, 12 microcirculation, S1P holds vasoconstrictor potency and modulates endothelial functions critical for immune cell interaction with the vessel wall, conferring S1P signalling with substantial importance in controlling vasoresponsiveness and blood flow regulation. 13 S1P, a phospholipid generated by two kinases (SphK1 and SphK2), mediates its specific responses via different G-protein coupled receptors (S1P [1] [2] [3] [4] [5] ), of which S1P 1 is currently the most studied with distinct effects on the vasculature and the immune-system. 11, 12 The activation of endothelial S1P 1 for instance, promotes relaxation of resistance arteries, 14, 15 increased barrier function or release of pro-inflammatory factors from storage granules, 16, 17 whereas the same receptor modulates lymphocyte egress and homing in the immune-system. [18] [19] [20] Besides the important role of S1P receptors in the regulation of critical vascular and immune cell functions, the involvement of S1P generating enzymes in related measures has also been shown. [21] [22] [23] [24] While Sphk1 activity modulates Ca 2þ sensitivity and thus, myogenic responsiveness in resistance arteries, 21, 25, 26 vascular barrier integrity, 27 mast-cell function, 28 and participates in NF-jB and TLR4 activation, 29, 30 there is only little known about SphK2-mediated effects in the vasculature and the immune-system besides its participation in maintenance of blood-brain barrier function, 31 its contribution to histone acetylation and gene expression, 32 and its role in the redistribution of blood-borne S1P into tissues. 33 With this study, we aimed to investigate the role of S1P and its generating enzymes in the BP responses to chronic Angiotensin II (AngII) treatment. We herein successfully demonstrate the critical importance of SphK2 in the pathogenesis of hypertension. Moreover, we highlight the role of plasma S1P to emphasize its importance as a chemotactic signal for immune cells, and expand on the immune-modulatory function of S1P by using the FDA approved drug Fingolimod, an agonist for four S1P receptors. Our findings support a crucial role for SphK2 activity in T-cell mobilization from lymph nodes and endothelial activation with critical implication for BP responses to AngII in vivo.
Methods
An expanded Methods section is available in the Supplementary Data online.
Animals
This investigation conforms to the Guide for Care and Use of Laboratory Animals published by the European Union (Directive 2010/63/EU). All animal care and experimental protocols were approved by the institutional animal ethics committees at the University of Barcelona (CEEA) and conducted in accordance with European animal protection laws. Commercially available wild-type (WT) mice (C57BL/6) were purchased from Janvier Laboratories (Le Genest St Isle, France). SphK1 , and B6.SJL-Ptprca Pepcb/BoyJC57 mice (all C57BL/6 background) were purchased from Jackson Laboratories (Charles River, Lyon, France). All mice were housed under a standard 12h:12h light-dark cycle, and had access to food and water ad libitum.
Generation of bone marrow chimeras (WT
SphK2-/-) CD45.1 (B6.SJL-Ptprca Pepcb/BoyJC57) mice (n = 8) were used to generate chimeric mice by ablating bone marrow using the chemotherapy drug busulfan as previously described. 34 Briefly, recipient reporter CD45.1 (B6.SJL-Ptprca Pepcb/BoyJC57) mice were subjected to three intraperitoneal injections of 30 mg/g body weight busulfan 7, 5, and 3 days prior to bone marrow transfer. All mice were treated with antibiotics (Enrofloxacin 0.06% in drinking water) for 15 days after starting the busulfan treatment. One week following the first busulfan administration, recipient mice were reconstituted with 5 Â 10 6 bone marrow cells derived from femur and tibia of adult Sphk2 -/-donor mice that were anaesthetized (isoflurane 2.5% at 1.5 L/min oxygen) before euthanasia through cervical dislocation. Bone marrow was injected into the tail vein of recipients. Mice were subjected to experiments 8 weeks after receiving the bone marrow.
Adoptive T-cell transfer experiments using Rag2
-/-mice Rag2 -/-mice were subjected to adoptive transfer of 10 7 T-cells from either WT mice (n = 6) or SphK2 -/-mice (n = 6) via tail vein injection as previously described. 7 After allowing 3 days for T-cell engraftment, mice were subjected to the induction of hypertension according to the experimental model described below.
Hypertension model
Hypertension was induced using AngII-releasing osmotic mini pumps as previously described. 35 In brief, WT or transgenic male and female mice (12 weeks old, gender equally distributed to all experimental groups, no sex-based differences in BP responses were present, see Supplementary material online, Table S1 ) were anesthetized with isoflurane (2.5% at 1.5 L/min oxygen) for subcutaneous implantation of osmotic mini-pumps (Alzet-1004; Charles River, L'Arbresle, France) containing AngII (1 lg/kg per min at an infusion rate of 11lL/h), or an equivalent volume of vehicle (Saline). 35 Systolic BP was measured in conscious mice using tail-cuff plethysmography (LE 5002, Panlab, Cornella, Spain) starting 4 days before pump implantation after an initial training period of 7 days. Experimental groups were the following: WT mice that received AngII (n = 65) and respective controls (n = 25); SphK1 -/-(n = 10) and SphK2 -/-mice that received AngII (n = 15) and respective controls (n = 10 for SphK1 Fingolimod (1 mg/kg in Saline, i.p.) was injected every 48 h after an initial daily injection period of 3 days starting either the day of minipump implantation (early treatment, n ¼ 10) or 2 weeks later (delayed treatment, n ¼ 8). SphK1 inhibitor N,N-Dimethylsphingosine (DMS) (0.5 mg/kg in Saline; i.v.) or SphK2 inhibitor ABC294640 (5 mg/kg in Saline; i.v.) was administered daily in a group of hypertensive WT mice (n = 6 per group) starting 2.5 weeks after pump implantation. A second SphK2 inhibitor K-145 (15 mg/kg in Saline; i.v.) was administered daily to another group of hypertensive WT mice 3 weeks after pump implantation (n = 6).
Four weeks after pump implantation, mice were anaesthetized (isoflurane 2.5% at 1.5 L/min oxygen) for whole blood collection before euthanasia through cervical dislocation.
Pressure myography
Mice (n = 6 per group) were euthanized by cervical dislocation. Vasoresponsiveness of isolated mesenteric arteries (2nd order, 150-200 lm) was determined as using a pressure myograph (Danish MyoTech P100; J.P. Trading, Aarhus, Denmark) as previously described. 36 Briefly, intraluminal pressure was reduced to 3 mmHg, a 
Statistical analysis
All data are expressed as mean ± SEM, where n is the number of animals. For comparison of multiple independent groups, a nonparametric 1-way ANOVA (Kruskal-Wallis) followed by a Dunn's test with exact P-value computation as a post hoc test for multiple comparisons. For the assessment of BP, myogenic responses, dose-response relationships and wallto-lumen ratio, data were analysed with a 2-way repeated-measures ANOVA; if a significant effect of treatment/genotype was observed, the Wilcoxon test with exact P-value computation was employed post hoc to assess the group differences. Differences were considered significant at error probabilities of P < _ 0.05. 
Results

SphK2 is involved in the development of AngII-induced hypertension
AngII perfusion increased BP in WT mice, but resulted in blunted BP responses in mice lacking one of the S1P generating enzymes (Sphk1 or Sphk2) ( Figure 1A) . Remarkably, genetic deletion of Sphk2 completely abolished the AngII effects on BP ( Figure 1A) . Furthermore, therapeutic administration of the SphK2 antagonists ABC294640 or K-145, but not the SphK1 antagonist N,N-Dimethylsphingosine (DMS), significantly reduced BP levels in WT mice subjected to AngII treatment ( Figure 1B) , suggesting a contribution of the SphK2 signalling axis in AngII-induced hypertension. 82 for WT mice, n = 6 per group, P = 0.0994 for multiple, unpaired comparisons).
AngII increases blood T-cell number in
T-cell mobilization from lymph nodes is required for the onset of hypertension
In order to test whether lymphocyte egress from lymph nodes was necessary for the development of hypertension, we used the immunemodulatory drug fingolimod (FTY720), which induces lymphopenia by preventing lymphocyte egress through S1P 1 receptor internalization in lymphocytes. 19, 20, 39 We studied whether Fingolimod-induced lymphopenia affected BP responses to AngII in WT mice using two different drug administration protocols. Mice received Fingolimod either directly after implanting AngII delivering pumps (early treatment) or 2 weeks after pump implantation (delayed treatment). Both treatment routines caused severe lymphopenia (Figure 2A) . The early treatment protocol mitigated the development of hypertension ( Figure 2B ). In contrast, delayed treatment had no effect on the already elevated BP in these mice ( Figure  2B ), indicating that T-cell mobilization from lymphoid tissue to the circulation is a crucial step required for the onset, but not the maintenance, of hypertension in response to AngII.
Haematopoietic SphK2 activity is mandatory for AngII-induced BP increase
In order to test whether haematopoietic SphK2 was involved in the development of hypertension, we generated chimeric mice. By reconstituting bone marrow of WT (CD45.1) mice with bone marrow from Figure SIIb) . Nonetheless, WT 
Supplementary material online,
SphK2 activity in haematopoietic cells determines changes in S1P levels
S1P, which acts as chemotactic signal for lymphocyte egress and homing, 13 was elevated in plasma of hypertensive WT mice ( Figure 3A) .
However, this effect was attenuated in SphK2 -/-mice ( Figure 3A) . AngIItreated WT Sphk2-/-mice presented plasma S1P levels similar to SphK2-deficient mice ( Figure 3B) , suggesting that the AngII-mediated increase of plasma S1P depends on haematopoietic SphK2 activity.
To test whether SphK2 activity in T-cells was needed to regulate plasma S1P levels, we used lymphocyte-deficient Rag2 -/-mice that received adoptive transfer of T-cells from WT mice or SphK2 -/-mice. S1P plasma levels after AngII treatment were similar in both groups ( Figure 3C ), suggesting that SphK2 in T-cells was not a main source of plasma S1P. Additionally, neither Fingolimod treatment regimen prevented the AngII-induced elevation of plasmatic S1P levels ( Figure 3D ), confirming that circulating T-cells did not regulate AngII-induced changes of plasma S1P levels.
SphK2 activity regulates vascular inflammation
Mesenteric arteries of hypertensive mice showed elevated markers of endothelial activation and inflammation ( Table 1 ) that might contribute to hypertension-associated endothelial dysfunction. Among them, vWF expression in the mesenteric endothelium ( Figure 4A : a, control and b, AngII) significantly augmented with hypertension, and associated to an enhanced CD3 þ T-cell accumulation at the artery wall ( Figure 4B : a, control and b, AngII). Notably, we also detected up-regulation of vascular SphK2 expression ( Figure 5C ). On the contrary, SphK2 -/-mice displayed an increased expression of endothelial vWF compared to WT control vessels ( Figure 4A : a, WT control and c, SphK2 -/-control). Likewise, those mice revealed endothelial dysfunction ( Figure 7A ), elevated expression of other endothelial activation marker ( Table 1 ) and an enhanced CD3 þ T-cell accumulation at mesenteric arteries ( Figure 4B : a, WT control and c, SphK2 -/-control).
Unexpectedly, AngII treatment in SphK2 -/-mice failed to induce further vascular inflammation ( Table 1 , Figure 4A /B: c, control and d, AngII). This might be attributable to an attenuated T-cell migration towards the vessel wall due to a sequestration of T-cells in the lymph nodes and thus, reduced T-cell numbers in the blood ( Figure 1C and D) . In vitro experiments utilizing cultured endothelial cells (bEND.5) suggested a T-cell-independent mechanism for AngII-mediated endothelial activation. Incubation of bEND.5 cells with S1P, AngII or the SphK2 antagonist ABC294640 significantly up-regulated vWF expression ( Figure 5A) . The here observed effect, by which AngII but not S1P attenuated the increase of vWF expression mediated through SphK2-inhibition ( Figure 5A) , aligns with data obtained in vivo, where AngII treatment normalized vWF plasma concentration of SphK2-deficient mice to WT control levels ( Figure 5B) . As expected, WT SphK2-/-mice revealed a vascular SphK2 expression similar to AngII-treated WT mice ( Figure 5C ), positioning vascular SphK2 as an important regulatory element for endothelial function.
Vascular SphK2 activity regulates mesenteric artery structure and function
In our model, accumulation of immune cells in mesenteric arteries of hypertensive WT mice ( Figure 6A : a, control and b, AngII) associated to hypertrophic remodelling marked by an increased wall-to-lumen ratio ( Figure 6B) , and an enlarged cross-sectional area ( Figure 6C) . AngII treatment increased wall stiffness as evident by an augmented b value (control: 7.897 ± 0.2118, n =6; AngII: 9.344±0.2130, n = 6; P = 0.0294) calculated from the leftward shifted stress-strain relationship (see Supplementary material online, Figure SIVa) . These effects most likely contributed to impaired vasodilatory responses to ACh ( Figure 7A) , enhanced vasoconstriction to PE ( Figure 7B ), and to an augmented myogenic response ( Figure 7C ) typical of hypertension. In accordance to their pro-inflammatory phenotype, Sphk2-deficient mice presented altered structure and function of mesenteric arteries as evident by an enlarged cross-sectional area ( Figure 6C) , impaired vasodilatory response to ACh ( Figure 7A ) and enhanced vasoconstriction to PE ( Figure 7B ) compared to WT control mice. Unlike WT mice, SphK2 -/-mice responded with a reduction of arterial cross-sectional area ( Figure  6C) , and an improved vasodilatory response to ACh to AngII treatment ( Figure 7A) . The basally enhanced myogenic response in these mice was normalized by AngII treatment to WT control levels ( Figure 7C) . In mice lacking SphK2 only in haematopoietic cells (WT SphK2-/-), AngII failed to induce structural alterations in mesenteric arteries as evident by a significantly lower wall thickness compared to hypertensive WT mice Targeting SphK2 in hypertension ( Figure 7D) . These data imply a regulatory role for SphK2 in the maintenance of adequate mesenteric artery function with prospect to orchestrating vascular responses to AngII.
Discussion
The present study emphasizes the involvement of S1P signalling in vascular and immune cell responses during experimental AngII-induced hypertension. Our data confirm a key role for S1P chemotaxis and T-cell mobilization at the onset of AngII-induced hypertension, and demonstrate that haematopoietic SphK2 activity is crucial for T-cell egress from the lymph nodes and hence, for the regulation of BP responses to AngII. Most importantly however, our data suggest that vascular inflammation alone is not predictive for the development of overt hypertension. In this respect, our findings point at a pathophysiologic role for the SphK2-S1P axis in the microvasculature. Although T-lymphocytes are recognized as important players in various models of hypertension, 7, 8 their precise role and underlying mechanisms are unclear. Our herein presented data put forward the idea that T-cells are essential for the onset of hypertension, but are dispensable at later stages. T-cell activation stimulated by mild BP elevation promotes the development of sustained hypertension in a feed forward fashion. 40 Consequently, blocking T-cell egress at the time of sympathetic and peripheral activation interferes with this cascade and prevents the development of hypertension in lymphopenic mice for instance, Rag-deficient mice 7 or mice preventatively treated with the immune-modulator Fingolimod. Fingolimod antagonizes S1P 1 on T-lymphocytes thus, regulating their egress from lymph nodes and thereby also preventing the recruitment of T-cells at sites of local inflammation 19 with potential consequences for vascular function and BP regulation. Our study has not directly elucidated upon vascular T-cell infiltration after Fingolimod treatment but others suggested that Fingolimod might fail to reduce the number of memory T-cells, 41 which reside in the vasculature and continually promote inflammation, whereas substances like Abatacept reverse already established hypertension. 38 In this respect, our findings confirm that S1P-receptor targeted immune-modulatory therapy fails as effective approach to controlling overt hypertension. In contrast, targeting other S1P signalling components yields more encouraging results as the inhibition of SphK2 reverses already established hypertension induced by AngII. The SphK2-S1P axis might be involved in different mechanisms contributing to the development of hypertension for instance, the generation of tissue-specific S1P and its release to the circulation thereby critically controlling lymphocyte egress and homing. 33, 42 A major determinant driving lymphocyte egress is the existing S1P gradient between tissue and blood. 42 An elevation of circulating S1P levels associates to several inflammation-associated diseases, including psoriasis, 43 inflammatory bowel disease, 44 multiple sclerosis 45 as well as hypertension, 46 ,47 supporting its critical role in immune cell trafficking. S1P 1 mediates Tlymphocyte egress from lymph nodes along the S1P gradient, 48 which is devoid in conditional-knockout mice that lack both S1P generating enzymes and thus, block the exit of lymphocytes from lymphoid organs. 49 In our mouse model, genetic deletion of SphK2 blunts the AngII-induced increase of plasmatic S1P and blocks the egress of lymphocytes from the lymph nodes, thereby preventing the elevation of circulating lymphocytes in the blood. The source of S1P driving this mechanism however, is still subject of controversial discussions. While studies have shown an involvement of lymphatic endothelial cells in the local production of S1P, 23 red blood cells (RBCs) have been discussed to mediate the transport of S1P from blood to lymphoid tissue in a process involving haematopoietic SphK2 activity. 33 Our findings agree with the concept that haematopoietic SphK2 is necessary for T-cell egress from secondary lymphoid tissue. Furthermore, our results show the critical role of haematopoietic SphK2, but not T-lymphocyte SphK2, in the AngII-induced increase of plasma S1P with critical implication for BP responses. A role of platelets in SphK2-dependent S1P generation during AngII-induced hypertension cannot be excluded since platelets are a main source of plasma S1P, and SphK2 the major isoform responsible for S1P generation and secretion in platelets. 50 The inverse relationship between T-cell accumulation in lymph nodes and circulating T-cells in the blood suggests that AngII might also promote T-cell mobilization from blood to tissues with possible consequences for BP responses to AngII. Blocking T-cell egress from the lymph nodes in the absence of haematopoietic SphK2 and thus, sufficient S1P gradient, triggers T-cell accumulation in lymphoid tissue and leads to decreased T-cells counts in the circulation. Although AngII-induced T-cell proliferation mediated through AngII receptors type 1 cannot be excluded, 51 our data support that AngII enhances T-cell trafficking between blood and lymphoid tissue and vice versa. Our findings support a 
regulatory link between T-cell egress and homing during AngII-induced hypertension, and assign haematopoietic SphK2 a critical role in the mediation of T-cell mobilization from lymph nodes to the blood.
The suggested SphK2-dependent T-cell mobilization from lymph nodes upon AngII treatment has potential implication for tissue inflammation. Especially, the accumulation of T-cells in mesenteric arteries of hypertensive mice, and its absence in response to AngII in mice with altered T-cell mobilization from the lymphoid organs confirms the significance of T-cell infiltration and accumulation in perivascular spaces for the development of vascular dysfunction and hence, hypertension. 7, 52, 53 Due to its location, SphK2 has also been conferred essential function in the regulation of transcription factors including NF-jB, 32, 54, 55 which has been proposed as important intrinsic mediator for inflammatory responses during hypertension. 56 The herein reported involvement in the regulation of endothelial activation markers confers SphK2 with potential significance for vascular inflammation and vascular dysfunction. S1P signalling-known for driving exocytosis of endothelial storage granules containing for instance vWF, 16, 17, 57 could potentially participate in endothelial activation during hypertension 57 through SphK2.
The enhancing effect on T-cell proliferation and pro-inflammatory cytokine production mediated by SphK2 deletion has already been shown in vitro, 58 but the possible physiological consequences for vascular function and thus, BP have not been reported before. Our current data indicate that chronic deregulation of SphK2 favours a pro-inflammatory/pro-thrombotic phenotype related to vascular dysfunction, but suggest that these vascular alterations alone are not sufficient for the development of overt hypertension. Specifically, the proinflammatory phenotype of SphK2 -/-mice that associates to impaired myogenic function and hence, peripheral resistance without consequences for BP might be due to compensation characterized by elevated heart rate, which is also reflected by a higher heart to body weight ratio compared to WT mice. This, of course, might have deleterious consequences long-term. Taken together, our findings suggest that the AngII-induced elevation of plasma S1P serves to attract T-lymphocytes from the lymph nodes to the circulation. Haematopoietic Sphk2 activity is crucially involved in this critical initial step for the development of hypertension by regulating S1P plasma concentration in response to AngII and hence, T-cell egress from lymph nodes thereby controlling their interaction with mesenteric arteries (see scheme Figure 8 ). Similar to AngII, S1P activates the artery endothelium thereby inducing the expression of pro-inflammatory cytokines as well as molecules necessary for T-cell adhesion, easing the way for T-cells to infiltrate and accumulate within the vascular wall and thus, altering vascular structure and function. Besides directing T-cell mobilization through its activity in the haematopoietic system, vascular SphK2 crucially regulates vascular inflammation by controlling vWF expression, pointing at a pathophysiologic role for the SphK2-S1P axis in the microvasculature, which might bear significant therapeutic potential to treat vascular dysfunction contributing to hypertension. by inducing S1P generation through SphK2 activation in platelets and/or RBCs and hence, increasing plasmatic S1P concentration. The inhibition of SphK2 in haematopoietic cells critically affects S1P generation in the plasma and thus, the generation of an S1P gradient necessary for T-cell egress allowing for an accumulation of T-cells within the lymph nodes. AngII, as well as S1P secreted after AngII stimulation, activate the mesenteric artery endothelium thereby inducing the expression of pro-inflammatory cytokines and molecules necessary for T-cell adhesion, easing the way for T-cells to infiltrate tissue and accumulate within the vascular wall. The resulting vascular inflammation leads to structural alterations with deleterious consequences for vasoresponsiveness and hence, for the regulation of BP and blood flow. Independent of T-cells, vascular SphK2 contributes to vascular inflammation in response to AngII by regulating vWF expression.
Targeting SphK2 in hypertension
